Schizophrenia Research
Volume 122, Issue 1 , Pages 206-212 , September 2010

The investigator and the IRB: A survey of depression and schizophrenia researchers

  • Bernard A. Fischer

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, 55 Wade Avenue, P.O. Box 21247, Baltimore, MD 21228, USA
    • Veterans Affairs Capital Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), VA Maryland Health Care System, 10 North Greene Street, Baltimore, MD 21201, USA
    • Corresponding Author InformationCorresponding author. Maryland Psychiatric Research Center P.O. Box 21247 Baltimore, MD 21228, USA. Tel.: +1 410 402 7113; fax: +1 410 402 7198.
    • ,
  • Praveen George

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, 55 Wade Avenue, P.O. Box 21247, Baltimore, MD 21228, USA
    • The Shriver Center, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA

Received 24 August 2009 ,Revised 15 December 2009 ,Accepted 21 December 2009.

References 

  1. Angell M. In: Drug Companies & Doctors: A Story of Corruption. vol. 56,(1):NY Rev Books; 2009;Available at http://www.nybooks.com/articles/22237 (Accessed 6/2009)
  2. Appelbaum PS, Grisso T. The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment. Law Hum Behav. 1995;19:105–126
  3. Burns J. Dispelling a myth: developing world poverty, inequality, violence, and social fragmentation are not good for outcome in schizophrenia. Afr. J. Psychiatry (Johannesbg). 2009;12:200–205
  4. Carpenter WT, Schooler N, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch. Gen. Psychiatry. 1997;54(5):401–407
  5. Carpenter WT, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, et al. Decisional capacity for informed consent in schizophrenia research. Arch. Gen. Psychiatry. 2000;57:533–538
  6. Charney DS, Nemeroff CB, Lewis L, et al. National Depressive and Manic Depressive Association consensus statement on the use of placebos in clinical trials of mood disorders. Arch. Gen. Psychiatry. 2002;59:262–270
  7. Chen DT, Meschita JF, Brott TG, Brown RD, Worrall BB, for the Swiss Investigators . Stroke genetic research and adults with impaired decision-making capacity: a survey of IRB and investigator practices. Stroke. 2008;39:2732–2735
  8. Cohen B, McGarvey E, Pinkerton R, Kryzhanivska L. Willingness and competence of depressed and schizophrenic inpatients to consent to research. J. Am. Acad. Psychiatry Law. 2004;32:134–143
  9. Department of Health and Human Services, Office for Human Research Protections. Code of Federal Regulations, Title 45: Public Welfare, Part 46: Protection of Human Subjects. Revised 2005. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm (Accessed 6/2009).
  10. Dunlop BW, Banja J. A renewed ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. J. Med. Ethics. 2009;35:384–389
  11. Dunn LB. Capacity to consent to research in schizophrenia: the expanding evidence base. Behav. Sci. Law. 2006;24:431–445
  12. Fischer BA. A summary of important documents in the field of research ethics. Schizophr. Bull. 2006;32(1):69–80
  13. Greene SM, Geiger AM, Haris EL, Altschuler A, Nekhlyudov L, Barton MB, et al. Impact of IRB requirements on a multicenter survey of prophylactic mastectomy outcomes. Ann. Epidemiol. 2006;16:275–278
  14. Grisso T, Appelbaum PS. The MacArthur Treatment Competence Study. III: Abilities of patients to consent to psychiatric and medical treatments. Law Hum Behav. 1995;19:149–174
  15. Grisso T, Appelbaum PS, Mulvey EP, Fletcher K. The MacArthur Treatment Competence Study. II: Measures of abilities related to competence to consent to treatment. Law Hum Behav. 1995;19:127–148
  16. Hirshon JM, Krugman SD, Witting MD, Furuno JP, Limcangco MR, Perisse AR, et al. Variability in institutional review board assessment of minimal-risk research. Acad. Emerg. Med. 2002;9(12):1417–1420
  17. Hummer M, Holzmeister R, Kemmler G, Eder U, Hofer A, Kurzthaler I, et al. Attitudes of patients with schizophrenia towards placebo-controlled clinical trials. J. Clin. Psychiatry. 2003;64:277–281
  18. Jeste DVV, Depp CA, Palmer BW. Magnitude of impairment in decisional capacity in people with schizophrenia compared to normal subjects: an overview. Schizophr. Bull. 2006;32(1):121–128
  19. Larson E, Bratts T, Zwanziger J, Stone P. A survey of IRB process in 68 U.S. hospitals. J Nurs Scholarsh. 2004;36(3):260–264
  20. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur. Psychiatry. 2001;16(7):418–423
  21. McWilliams R, Hoover-Fong J, Hamosh A, Beck S, Beaty T, Cutting G. Problematic variation in local institutional review of a multicenter genetic epidemiology study. JAMA. 2003;290:360–366
  22. National Bioethics Advisory Commission . Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. In: Report and Recommendations. Vol. I:Washington: U.S. Government Printing Office; 1998;
  23. Oldham JM, Haimowitz S, Delano SJ. Protection of persons with mental disorders from research risk. Arch. Gen. Psychiatry. 1999;56:688–693
  24. Roberts LW, Hammond KG, Hoop J. An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols. Am. J. Psychiatry. 2006;163:2002–2004
  25. Roth DE. Humanitarian aid and medical research: an illusion of dichotomy in international health. CMAJ. 2001;164:1862–1864
  26. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr. Res. 2005;80:1–8
  27. Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?. Schizophr. Res. 1999;211–218
  28. Wendler D, Emanuel EJ, Lie RK. The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs?. Am. J. Pub. Health. 2004;94:923–928

PII: S0920-9964(09)00610-0

doi: 10.1016/j.schres.2009.12.019

Schizophrenia Research
Volume 122, Issue 1 , Pages 206-212 , September 2010

Article Tools